SCHEMBL4066630

SCHEMBL4066630

Cc1ccc(-c2cc3ncnc(N(CC4=COCO4)Cc4ccccc4)c3s2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 3/20 0.41
IKBKB O14920 1/20 0.37
STK17B O94768 4/20 0.35
EGFR P00533 3/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35
TUBA3E Q6PEY2 1/20 0.35
TUBA1A Q71U36 1/20 0.35
TUBA1C Q9BQE3 1/20 0.35
TUBB6 Q9BUF5 1/20 0.35
TUBB2B Q9BVA1 1/20 0.35
TUBB1 Q9H4B7 1/20 0.35
FLT1 P17948 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4075052 0.94 MAP3K8 (0.45) MAP3K8IKBKBSTK17BEGFRFLT1
SCHEMBL4069660 0.94 IKBKB (0.41) MAP3K8IKBKBSTK17BEGFRFLT1
SCHEMBL4075080 0.93 MAP3K8 (0.38) MAP3K8IKBKBSTK17BEGFRFLT1
SCHEMBL3938279 0.91 FLT1 (0.46) MAP3K8IKBKBSTK17BEGFRFLT1
SCHEMBL4068418 0.91 KIT (0.43) MAP3K8IKBKBSTK17BEGFRFLT1
SCHEMBL4064216 0.91 STK17B (0.41) MAP3K8IKBKBSTK17BEGFRFLT1
SCHEMBL4067150 0.90 RAB9A (0.45) MAP3K8IKBKBSTK17BEGFRKIT
SCHEMBL4071472 0.90 IKBKB (0.35) MAP3K8IKBKBSTK17BEGFRFLT1
SCHEMBL4074723 0.90 IKBKB (0.40) MAP3K8IKBKBSTK17BEGFRFLT1
SCHEMBL4071124 0.89 FDPS (0.38) MAP3K8IKBKBSTK17BEGFRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 MAP3K8 1493/4885IKBKB 2889/4885STK17B 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.